Would you recommend PARP inhibitor maintenance to a germline-negative 76-year-old with high-grade serous ovarian cancer after complete radiographic response to 6 cycles of neoadjuvant chemotherapy who declines surgery, but did not have enough tissue at time of diagnosis to perform NGS?